"Securing FDA marketing authorisation for Versius is a significant milestone for CMR and, most importantly, for hospitals and patients who will now have greater access to robotic-assisted surgery." - Mark Slack, CMR's chief medical officer.
CMR Surgical's headquarters and manufacturing site remain in Cambridge, with backing from international investors, including the Japanese tech giant SoftBank and China's Tencent. This demonstrates strong global investor confidence.
The Versius system, designed to replicate the movements of the human arm and enhance surgeon precision, is already the second-most widely used robotic surgical system globally, having completed more than 26,000 surgeries.
CMR has raised approximately $1 billion since its inception, highlighting its rapid growth and recognition in the global medtech sector, particularly after its $600 million funding round in 2021.
Collection
[
|
...
]